- 作者：Martí ; n Ruiz Ortiz ; maruor@gmail.com ; Elí ; as Romo ; Dolores Mesa ; Mó ; nica Delgado ; Cristina Ló ; pez ; Juan Carlos Castillo ; Amador Ló ; pez Granados ; Manuel Anguita ; José ; Marí ; a Arizó ; n ; José ; Suá ; rez de Lezo
- 关键词：Fibrilació ; n auricular no valvular ; Octogenarios ; Anticoagulantes
- 刊名：Cardiocore
- 出版年：2011
- 出版时间：October-December 2011
- 年：2011
- 卷：46
- 期：4
- 页码：155-160
- 全文大小：249 K
Background and objectives
The objective of the present study is to describe clinical features and antithrombotic treatment of octogenarian patients with nonvalvular atrial fibrillation (NVAF) seen in a general cardiology outpatient clinic.
Patients and method
From February 1st, 2000 to June 30th, 2009, all patients aged ?0 years with NVAF seen in two cardiology clinics were included in a prospective management protocol. All cardioembolic risk factors (CERF) were registered, as well as absolute contraindications to anticoagulation. This treatment was offered to all those patients without contraindications and with at least one CERF, apart from advanced age. The decision to include was left to the physician responsible for those without any additional CERF.
Results
A total of 269 patients were included in the study (87 male, mean age 83 ¡À 3 years). Most frequent CERF was: hypertension (73 % ), diabetes mellitus (25 % ), heart failure (17 % ), prior embolic event (16 % ) and coronary heart disease (9 % ). A total of 65 patients (24 % ) presented absolute contraindications to anticoagulation, and, from the rest, 164 patients received anticoagulants (80 % of those without contraindication and 61 % of the whole series). Patients on anticoagulants were younger (83 ¡À 3 years versus 84 ¡À 4 years, p = .001), had a higher frequency of hypertension (77 % versus 66 % , p < 0.05) and coronary heart disease (13 % versus 3 % , p < .01). Of the patients not receiving anticoagulants, 95 % received platelet aggregation inhibitors, mainly aspirin (87 % ).
Conclusion
Octogenarian patients with NVAF have a high frequency of cardioembolic risk factors, as well as absolute contraindications to anticoagulation. After the protocolled study, 61 % received anticoagulant treatment.